国产成人精品高清久久_好姑娘影视在线观看高清_99久久久久久久久_欧美涩涩网_久久国产精品91_9色网站

美國ChemDiv  
ChemDiv公司已經有20年的歷史，目前在全球擁有超過1500名高端客戶。占到全球市場份額的40%。公司致力于為藥物發現，制藥和生物技術發展的合作伙伴提供創新性解決方案；努力讓工業和學術研究進行更好的融合，為威脅生命的疾病帶來新的解決方法。公司擁有全球最大的小分子化合物庫，除了目前庫存的125萬種化合物以外，每年以15萬種新化合物的速度遞增。此次交流對中國科研工作者與國際大型藥物篩選公司接觸和了解起到了重要作用，一定程度上為今后的科研工作開拓了思路。

ChemDiv is a fully integrated discovery and development Contract Research Organization (CRO) headquartered in San Diego, CA, USA, with subsidiaries in Russia and Ukraine, business and logistics operations around the world. Our organisation collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value clinical inflection points. One of the industry's most established CROs, ChemDiv offers Integrated Discovery outSource solutions that cover a complete range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market. With successful 20 years business record in life sciences and over 500 research associates employed globally, we put forward unique translational capabilities from Research to Clinical Development.

ChemDiv's expertise in rational drug design, synthetic and medicinal chemistry in various therapeutic areas of target classes has allowed it to successfully execute collaborations with leading Pharmaceutical and Biotechnology companies leveraging company's core capabilities in chemistry and biology. We also provide translational research and development support to help bring candidates forward in development through offering a comprehensive package of pre-clinical and clinical services. By applying its strong in-house R&D expertise and a blend of unique business models, ChemDiv is exceptionally positioned to provide its partners with Proof of Concept data in less time and at a fraction of the cost typically seen in the pharmaceutical industry therefore mitigating very high risks associated with the full scale clinical development.